Jaiwant Rangi, MD, FACEEndocrinologist | Founder, Lower The Dose® | Speaker

Strategic Approaches to Managing Obesity-Related Diabetes

15 Jul 2026 · 1 min

Watch on YouTube

0:41

In this segment, Dr. Jaiwant Rangi outlines the treatment pathway for patients with mild obesity‑related type 2 diabetes. He recommends initiating therapy with a GLP‑1 receptor agonist combined with metformin as the standard pharmacologic regimen. For individuals with significant obesity, he specifies surgical criteria: bariatric surgery is considered when BMI exceeds 35 kg/m² with metabolic complications or when BMI exceeds 40 kg/m² regardless of complications. He emphasizes the importance of a daily caloric deficit of 500–700 kcal to support weight loss and improve glycemic control. The advice balances medication, possible surgical intervention, and lifestyle modification.

Chapters

Then comes mild obesity-related diabetes. In that case, again, the pattern is very similar. GLP-1 agonist, metformin, but sometimes if there's an issue with significant obesity or weight, then we may consider bariatric surgery if their body mass index is more than 35 and they have metabolic complications, or if their body mass index is more than 40. In this case, severe or significant calorie deficit diet is very important. So I recommend these patients to have a deficit of at least 500 to 700 calories less every day.